2026-04-14T06:23:05Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1803722025-11-20T15:04:03Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Genescà, Eulàlia author Morgades, Mireia author González Gil, Celia author Fuster Tormo, Francisco author Haferlach, Claudia author Meggendorfer, Manja author Montesinos, Pau author Barba, Pere author Gil, Cristina author Coll, Rosa author Moreno, María José author Martínez Carballeira, Daniel author García Cadenas, Irene author Vives, Susana author Ribera, Jordi author González Campos, José author Díaz Beyà, Marina author Mercadal, Santiago author Artola, María Teresa author Cladera, Antonia author Tormo, Mar author Bermúdez, Arancha author Vall Llovera, Ferran author Martínez Sánchez, Pilar author Amigo, María Luz author Monsalvo, Silvia author Novo, Andrés author Cervera, Marta author García Guiñon, Antonio author Ciudad, Juana author Cervera, José author Hernández Rivas, Jesús María author Granada, Isabel author Haferlach, Torsten author Orfao, Alberto author Solé, Francesc author Ribera, Josep Maria author 2021-10-04T07:32:18Z 2021-10-04T07:32:18Z 2021-10-01 2021-10-01T11:41:04Z The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients. Citogenètica humana Leucèmia Pronòstic mèdic Human cytogenetics Leukemia Prognosis Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)